Literature DB >> 20571502

Genome-wide gene expression profiling of the Angelman syndrome mice with Ube3a mutation.

Daren Low1, Ken-Shiung Chen.   

Abstract

Angelman syndrome (AS) is a human neurological disorder caused by lack of maternal UBE3A expression in the brain. UBE3A is known to function as both an ubiquitin-protein ligase (E3) and a coactivator for steroid receptors. Many ubiquitin targets, as well as interacting partners, of UBE3A have been identified. However, the pathogenesis of AS, and how deficiency of maternal UBE3A can upset cellular homeostasis, remains vague. In this study, we performed a genome-wide microarray analysis on the maternal Ube3a-deficient (Ube3a(m-/p+)) AS mouse to search for genes affected in the absence of Ube3a. We observed 64 differentially expressed transcripts (7 upregulated and 57 downregulated) showing more than 1.5-fold differences in expression (P<0.05). Pathway analysis shows that these genes are implicated in three major networks associated with cell signaling, nervous system development and cell death. Using quantitative reverse-transcription PCR, we validated the differential expression of genes (Fgf7, Glra1, Mc1r, Nr4a2, Slc5a7 and Epha6) that show functional relevance to AS phenotype. We also show that the protein level of melanocortin 1 receptor (Mc1r) and nuclear receptor subfamily 4, group A, member 2 (Nr4a2) in the AS mice cerebellum is decreased relative to that of the wild-type mice. Consistent with this finding, expression of small-interfering RNA that targets Ube3a in P19 cells caused downregulation of Mc1r and Nr4a2, whereas overexpression of Ube3a results in the upregulation of Mc1r and Nr4a2. These observation help in providing insights into the genesis of neurodevelopmental phenotype of AS and highlight specific area for future research.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20571502      PMCID: PMC2987484          DOI: 10.1038/ejhg.2010.95

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  33 in total

1.  Molecular cloning of a human, hemicholinium-3-sensitive choline transporter.

Authors:  S Apparsundaram; S M Ferguson; A L George; R D Blakely
Journal:  Biochem Biophys Res Commun       Date:  2000-10-05       Impact factor: 3.575

2.  A family with emotionally precipitated drop seizures.

Authors:  L KIRSTEIN; B P SILFVERSKIOLD
Journal:  Acta Psychiatr Neurol Scand       Date:  1958

3.  Distinct phenotypes distinguish the molecular classes of Angelman syndrome.

Authors:  A C Lossie; M M Whitney; D Amidon; H J Dong; P Chen; D Theriaque; A Hutson; R D Nicholls; R T Zori; C A Williams; D J Driscoll
Journal:  J Med Genet       Date:  2001-12       Impact factor: 6.318

4.  Angelman syndrome associated with oculocutaneous albinism due to an intragenic deletion of the P gene.

Authors:  C Fridman; N Hosomi; M C Varela; A H Souza; K Fukai; C P Koiffmann
Journal:  Am J Med Genet A       Date:  2003-06-01       Impact factor: 2.802

5.  The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology.

Authors:  Scott V Dindot; Barbara A Antalffy; Meenakshi B Bhattacharjee; Arthur L Beaudet
Journal:  Hum Mol Genet       Date:  2007-10-16       Impact factor: 6.150

6.  Difference in methylation patterns within the D15S9 region of chromosome 15q11-13 in first cousins with Angelman syndrome and Prader-Willi syndrome.

Authors:  J Clayton-Smith; D J Driscoll; M F Waters; T Webb; T Andrews; S Malcolm; M E Pembrey; R D Nicholls
Journal:  Am J Med Genet       Date:  1993-10-01

7.  Common precursors for neural and mesectodermal derivatives in the cephalic neural crest.

Authors:  A Baroffio; E Dupin; N M Le Douarin
Journal:  Development       Date:  1991-05       Impact factor: 6.868

8.  The NR4A subgroup: immediate early response genes with pleiotropic physiological roles.

Authors:  Megan A Maxwell; George E O Muscat
Journal:  Nucl Recept Signal       Date:  2006-02-08

9.  Mecp2-null mice provide new neuronal targets for Rett syndrome.

Authors:  Rocio G Urdinguio; Lidia Lopez-Serra; Pilar Lopez-Nieva; Miguel Alaminos; Ramon Diaz-Uriarte; Agustin F Fernandez; Manel Esteller
Journal:  PLoS One       Date:  2008-11-07       Impact factor: 3.240

10.  Retinoic acid induces embryonal carcinoma cells to differentiate into neurons and glial cells.

Authors:  E M Jones-Villeneuve; M W McBurney; K A Rogers; V I Kalnins
Journal:  J Cell Biol       Date:  1982-08       Impact factor: 10.539

View more
  7 in total

Review 1.  Pharmacological therapies for Angelman syndrome.

Authors:  Wen-Hann Tan; Lynne M Bird
Journal:  Wien Med Wochenschr       Date:  2016-01-12

2.  UBE3A regulates the transcription of IRF, an antiviral immunity.

Authors:  Ryohei Furumai; Kota Tamada; Xiaoxi Liu; Toru Takumi
Journal:  Hum Mol Genet       Date:  2019-06-15       Impact factor: 6.150

3.  Of mothers and myelin: Aberrant myelination phenotypes in mouse model of Angelman syndrome are dependent on maternal and dietary influences.

Authors:  Mark D Grier; Robert P Carson; Andre H Lagrange
Journal:  Behav Brain Res       Date:  2015-05-28       Impact factor: 3.332

4.  Drosophila Ube3a regulates monoamine synthesis by increasing GTP cyclohydrolase I activity via a non-ubiquitin ligase mechanism.

Authors:  Faiza Ferdousy; William Bodeen; Kyle Summers; Olugbenga Doherty; O'Neil Wright; Nahed Elsisi; George Hilliard; Janis M O'Donnell; Lawrence T Reiter
Journal:  Neurobiol Dis       Date:  2010-12-13       Impact factor: 5.996

5.  E6AP in the brain: one protein, dual function, multiple diseases.

Authors:  Jimmy El Hokayem; Zafar Nawaz
Journal:  Mol Neurobiol       Date:  2013-10-05       Impact factor: 5.590

Review 6.  UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome.

Authors:  Ype Elgersma; Monica Sonzogni
Journal:  Dev Med Child Neurol       Date:  2021-02-04       Impact factor: 5.449

7.  Neurodevelopmental Underpinnings of Angelman Syndrome.

Authors:  Guohui Li; Shenfeng Qiu
Journal:  J Bioanal Biomed       Date:  2014-11-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.